Bio-Techne Corporation (TECH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 739 | 931 | 1,106 | 1,137 | 1,159 | 1,220 | 1,215 | 1,207 |
| Operating profit | $m | 102 | 252 | ||||||
| Net profit | $m | 229 | 140 | 272 | 285 | 168 | 73 | 182 | 300 |
| EPS reported | $ | 0.46 | 1.16 | ||||||
| Operating cashflow per share | $ | 1.83 | 1.89 | ||||||
| Capex per share | $ | 0.20 | 0.16 | ||||||
| FCF per share | $ | 1.63 | 1.73 | ||||||
| Free cash flow | $m | 257 | 263 | ||||||
| Net debt | $m | 184 | -50 | ||||||
| Book value equity | $m | 1,919 | 2,108 | ||||||
| Book value per share | $ | 12.01 | 13.43 | ||||||
| Number of shares | m | 159.72 | 157.01 | ||||||
| DPS (TTM paid) | $ | 0.32 | 0.40 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 111.85 | 105.23 | ||||||
| P/B LTM | x | 4.22 | 3.84 | ||||||
| P/S LTM | x | 6.64 | 6.67 | ||||||
| P/FCF LTM | x | 31.59 | 30.79 | ||||||
| EV/EBITDA LTM | x | 38.67 | 24.42 | ||||||
| EV/Sales LTM | x | 6.88 | 9.39 | ||||||
| Earnings Yield LTM | % | +0.89% | +0.95% | ||||||
| FCF Yield | % | +3.17% | +3.25% | ||||||
| Quality | |||||||||
| ROE | % | +3.83% | +5.49% | ||||||
| ROIC | % | +3.18% | +4.75% | ||||||
| Operating margin | % | +8.38% | +12.70% | ||||||
| Gross margin | % | +64.80% | +64.96% | ||||||
| FCF/Sales | % | +21.03% | +22.27% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -56.19% | +10.48% | ||||||
| Sales Growth YoY | % | +5.23% | +4.83% | ||||||
| Net Income Growth YoY | % | -56.34% | +8.18% | ||||||
| FCF Growth | % | +8.66% | +11.49% | ||||||
| Operating Profit Growth | % | -50.53% | +21.87% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.62% | +0.44% | ||||||
| Dividend Growth | % | 0.00% | +25.00% | ||||||
| Payout Ratio | % | +68.59% | +46.13% | ||||||
| FCF/Debt | x | 0.58 | 0.91 | ||||||
| Net Debt/EBITDA | x | 1.30 | 0.31 | ||||||
| EBIT/Net interest | x | 12.02 | 14.64 | ||||||
| Net debt/market cap | % | +4.27% | +1.90% | ||||||
| Net debt/Equity | x | 0.10 | -0.02 | ||||||
| Gross debt/equity | x | 0.23 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free